Research
Hormonal
GLP-1 agonists (specifically semaglutide and liraglutide) reduce Major Adverse Cardiovascular Events (MACE) by 12-26% in patients with type 2 diabetes and obesity.
If you have type 2 diabetes and obesity, ask your doctor about the heart benefits of GLP-1 drugs. They can significantly reduce your risk of heart attacks and strokes, independent of weight loss.
StrongSupportsVERY_HIGH confidence
Semaglutide (SUSTAIN-6): –26% (HR 0.74); Liraglutide (LEADER): –13% (HR 0.87)
Why this rating
Based on dedicated Cardiovascular Outcome Trials (CVOTs).
Source
GLP-1 and GIP analogues in the treatment of obesity – Current State of Knowledge
Marta Grycan et al. · Biuletyn Głównej Biblioteki Lekarskiej · 2025
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →